Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
City AM
—
— Alixorexton Data From Seven-Week Open-Label Extension Period Demonstrated Sustained Improvements in Patient-Reported Disease Severity, Cognitive Functioning and Fatigue— — Alixorexton Was Generally Well Tolerated at All Doses Tested — — Phase 3 Brilliance NT1 Study of Alixorexton in Patients With Narcolepsy Type 1 Is Ongoing —